4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 94,444.44% | 500.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 94,444.44% | 500.00% | |||
| Cost of Revenue | 21.74% | -1.49% | |||
| Gross Profit | 158.50% | 1.64% | |||
| SG&A Expenses | 7.86% | 2.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.96% | -0.67% | |||
| Operating Income | 125.12% | 0.79% | |||
| Income Before Tax | 134.10% | -4.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 134.10% | -4.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 134.10% | -4.06% | |||
| EBIT | 125.12% | 0.79% | |||
| EBITDA | 127.77% | 0.97% | |||
| EPS Basic | 129.95% | -3.69% | |||
| Normalized Basic EPS | 131.31% | 0.33% | |||
| EPS Diluted | 129.95% | -3.69% | |||
| Normalized Diluted EPS | 131.31% | 0.33% | |||
| Average Basic Shares Outstanding | 13.88% | 0.36% | |||
| Average Diluted Shares Outstanding | 13.88% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||